Home › Compare › RAIFF vs ABBV
RAIFF yields 2.65% · ABBV yields 3.06%● Live data
📍 RAIFF pulled ahead of the other in Year 3
Combined, RAIFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RAIFF + ABBV for your $10,000?
Raiffeisen Bank International AG, together with its subsidiaries, provides corporate, retail, and investment banking services. The company offers cross border accounts; and cash management services, such as account, reporting, payment, clearing, settlement, and cash pooling services; electronic banking; and SEPA and cross-border payments to billing solutions. It also provides investor services, including custody and fund administration services, as well as execution services comprising electronic sales trading, direct market access, and fund brokerage services; trade, working capital, export, sustainable, and real estate finance services, as well as commodity and structured trade, project, and supply chain finance products; and cards. In addition, the company offers bank guarantees, sureties, and letters of credit, as well as documentary collection products; hedging, factoring, and leasing services; and fixed income, money market and securities, asset management, and structured products for corporate and institutional customers. Further, it arranges syndicated loans and structure asset based finance transactions; and assists clients in mergers, acquisitions, sales, and privatizations. As of December 31, 2020, the company operated through a network of 1,857 business outlets in Central, Southeastern, and Eastern Europe. Raiffeisen Bank International AG was founded in 1886 and is headquartered in Vienna, Austria.
Full RAIFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.